Low‐dose IL‐2 has been effective in chronic graft‐versus‐host disease to promote Treg proliferation and thymic export, rescue IL‐7 and IL‐15 levels, while showing a minimal effect on Teffs;126 and (iii) using adoptive transfer of ex vivo stimulated and expanded Tregs from patients’ peripheral blood mononuclear cells to ameliorate type I diabetes or delay solid organ transplant rejection. Here, IL7 is linked to type 1 diabetes mellitus.